UB Paderborn / Katalog / Suche / in CDI

1 – 15 von 15

Sortiert nach

Prostate cancer screening： and yet it moves

Asian journal of andrology, 2015-05, Vol.17 (3), p.437-438

2015

Volltextzugriff (PDF)

Screening and Prostate-Cancer Mortality in a Randomized European Study

The New England journal of medicine, 2009-03, Vol.360 (13), p.1320-1328

2009

Volltextzugriff (PDF)

Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up

The Lancet (British edition), 2014-12, Vol.384 (9959), p.2027-2035

2014

Volltextzugriff (PDF)

Prostate-Cancer Mortality at 11 Years of Follow-up

The New England journal of medicine, 2012-03, Vol.366 (11), p.981-990

2012

Volltextzugriff (PDF)

Screening for Prostate Cancer Decreases the Risk of Developing Metastatic Disease: Findings from the European Randomized Study of Screening for Prostate Cancer (ERSPC)

European urology, 2012-11, Vol.62 (5), p.745-752

2012

Volltextzugriff (PDF)

Comment on the US Preventive Services Task Force's Draft Recommendation on Screening for Prostate Cancer

European urology, 2012-04, Vol.61 (4), p.851-854

2012

Volltextzugriff (PDF)

Quantitative DNA methylation analysis of genes coding for kallikrein-related peptidases 6 and 10 as biomarkers for prostate cancer

Epigenetics, 2012-09, Vol.7 (9), p.1037-1045

2012

Volltextzugriff (PDF)

Is further screening of men with baseline PSA < 1 ng ml(-1) worthwhile? The discussion continues-Results of the Swiss ERSPC (Aarau)

International journal of cancer, 2015-08, Vol.137 (3), p.553-559

2015

Volltextzugriff (PDF)

Differences among Men on Active Surveillance for Very Low-Risk Prostate Cancer Detected Through Population-Based versus Opportunistic Prostate-Specific Antigen-Screening

Urologia internationalis, 2015-01, Vol.94 (3), p.330-336

2015

Volltextzugriff (PDF)

In prostatism patients the ratio of human glandular kallikrein to free PSA improves the discrimination between prostate cancer and benign hyperplasia within the diagnostic “gray zone” of total PSA 4 to 10 ng/mL

Urology (Ridgewood, N.J.), 1998-09, Vol.52 (3), p.360-365

1998

Volltextzugriff (PDF)

A (-5, -7) ProPSA based artificial neural network to detect prostate cancer

European urology, 2006-11, Vol.50 (5), p.1014-1020

2006

Volltextzugriff (PDF)

Human glandular kallikrein as a tool to improve discrimination of poorly differentiated and non-organ-confined prostate cancer compared with prostate-specific antigen

Urology (Ridgewood, N.J.), 2000-04, Vol.55 (4), p.481-485

2000

Volltextzugriff (PDF)

A Multicenter Clinical Trial On the Use of Complexed Prostate Specific Antigen in Low Prostate Specific Antigen Concentrations

The Journal of urology, 2003-10, Vol.170 (4), p.1175-1179

2003

Volltextzugriff (PDF)

Selective application of tumor markers PSA

Therapeutische Umschau, 2008-09, Vol.65 (9), p.493

2008

Volltextzugriff (PDF)

PROSPECTIVE DETECTION OF CLINICALLY RELEVANT PROSTATE CANCER IN THE PROSTATE SPECIFIC ANTIGEN RANGE 1 TO 3 NG./ML. COMBINED WITH FREE-TO-TOTAL RATIO 20% OR LESS: THE AARAU EXPERIENCE

The Journal of urology, 2001-09, Vol.166 (3), p.851-855

2001

Volltextzugriff (PDF)

1 – 15 von 15

Suche als RSS-Feed

Aktive Filter

KollektionWiley Online Library (Online service)

KollektionMEDLINE

ThemaMale

ThemaProstatic Neoplasms - Diagnosis

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(15)
Mit Volltextzugriff
(12)

Publikationsform

Artikel
(15)

Sprache

Erscheinungsjahr

n.n

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Prostate cancer screening： and yet it moves

Screening and Prostate-Cancer Mortality in a Randomized European Study

Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up

Prostate-Cancer Mortality at 11 Years of Follow-up

Screening for Prostate Cancer Decreases the Risk of Developing Metastatic Disease: Findings from the European Randomized Study of Screening for Prostate Cancer (ERSPC)

Comment on the US Preventive Services Task Force's Draft Recommendation on Screening for Prostate Cancer

Quantitative DNA methylation analysis of genes coding for kallikrein-related peptidases 6 and 10 as biomarkers for prostate cancer

Is further screening of men with baseline PSA < 1 ng ml(-1) worthwhile? The discussion continues-Results of the Swiss ERSPC (Aarau)

Differences among Men on Active Surveillance for Very Low-Risk Prostate Cancer Detected Through Population-Based versus Opportunistic Prostate-Specific Antigen-Screening

In prostatism patients the ratio of human glandular kallikrein to free PSA improves the discrimination between prostate cancer and benign hyperplasia within the diagnostic “gray zone” of total PSA 4 to 10 ng/mL

A (-5, -7) ProPSA based artificial neural network to detect prostate cancer

Human glandular kallikrein as a tool to improve discrimination of poorly differentiated and non-organ-confined prostate cancer compared with prostate-specific antigen

A Multicenter Clinical Trial On the Use of Complexed Prostate Specific Antigen in Low Prostate Specific Antigen Concentrations

Selective application of tumor markers PSA

PROSPECTIVE DETECTION OF CLINICALLY RELEVANT PROSTATE CANCER IN THE PROSTATE SPECIFIC ANTIGEN RANGE 1 TO 3 NG./ML. COMBINED WITH FREE-TO-TOTAL RATIO 20% OR LESS: THE AARAU EXPERIENCE

Aktive Filter

Suchergebnisse filtern